These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16391410)

  • 1. Virus safety of intravenous immunoglobulin: future challenges.
    Boschetti N; Stucki M; Späth PJ; Kempf C
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):333-44. PubMed ID: 16391410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.
    Kempf C; Stucki M; Boschetti N
    Biologicals; 2007 Mar; 35(1):35-42. PubMed ID: 16581263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The process: New methods of purification and viral safety.
    Schleis TG
    Pharmacotherapy; 2005 Nov; 25(11 Pt 2):73S-77S. PubMed ID: 16229677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.
    Lee DC; Miller JL; Petteway SR
    Haemophilia; 2002 Mar; 8 Suppl 2():6-9. PubMed ID: 11966845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with the viral safety of immunoglobulins.
    Hellstern P
    Blood Coagul Fibrinolysis; 1994 Dec; 5 Suppl 3():S31-4; discussion S35. PubMed ID: 7749046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulins: evolution of commercial IVIG preparations.
    Hooper JA
    Immunol Allergy Clin North Am; 2008 Nov; 28(4):765-78, viii. PubMed ID: 18940573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process.
    Trejo SR; Hotta JA; Lebing W; Stenland C; Storms RE; Lee DC; Li H; Petteway S; Remington KM
    Vox Sang; 2003 Apr; 84(3):176-87. PubMed ID: 12670366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
    Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
    Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
    Radomski KU; Lattner G; Schmidt T; Römisch J
    BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
    Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
    BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving perspectives in product safety for haemophilia.
    Farrugia A
    Haemophilia; 2002 May; 8(3):236-43. PubMed ID: 12010417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
    Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
    Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography.
    Lebing W; Remington KM; Schreiner C; Paul HI
    Vox Sang; 2003 Apr; 84(3):193-201. PubMed ID: 12670368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An enhanced viral safety of blood preparations].
    Zhiburt EB
    Vopr Virusol; 2004; 49(4):46-8. PubMed ID: 15293512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to avoid virus transmissions by biopharmaceutic products.
    Werz W; Hoffmann H; Haberer K; Walter JK
    Arch Virol Suppl; 1997; 13():245-56. PubMed ID: 9413543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
    Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
    Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral safety characteristics of Flebogamma DIF, a new pasteurized, solvent-detergent treated and Planova 20 nm nanofiltered intravenous immunoglobulin.
    Caballero S; Nieto S; Gajardo R; Jorquera JI
    Biologicals; 2010 Jul; 38(4):486-93. PubMed ID: 20350815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging viral diseases and infectious disease risks.
    Tapper ML
    Haemophilia; 2006 Mar; 12 Suppl 1(Suppl 1):3-7; discussion 26-8. PubMed ID: 16445811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.